Literature DB >> 25806206

Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study.

Niki Karachaliou1, Jia Wei2, Ana Daniela Marques3, Rafael Rosell4.   

Abstract

Entities:  

Year:  2013        PMID： 25806206      PMCID： PMC4367650          DOI： 10.3978/j.issn.2218-6751.2012.11.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

Authors:  Cesare Gridelli; Fortunato Ciardiello; Ciro Gallo; Ronald Feld; Charles Butts; Vittorio Gebbia; Paolo Maione; Floriana Morgillo; Giovenzio Genestreti; Adolfo Favaretto; Natasha Leighl; Rafal Wierzbicki; Saverio Cinieri; Yasmin Alam; Salvatore Siena; Giampaolo Tortora; Raffaella Felletti; Ferdinando Riccardi; Gianfranco Mancuso; Antonio Rossi; Flavia Cantile; Ming-Sound Tsao; Mauro Saieg; Gilda da Cunha Santos; Maria Carmela Piccirillo; Massimo Di Maio; Alessandro Morabito; Francesco Perrone
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

2.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Authors:  Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru Calin Grigorescu; Carina Hillenbach; Hrefna Kristin Johannsdottir; Barbara Klughammer; Emilio Esteban Gonzalez
Journal:  Lancet Oncol       Date:  2012-01-24       Impact factor: 41.316

3.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

4.  Treatment of advanced non-small-cell lung cancer in special populations.

Authors:  Rogerio C Lilenbaum
Journal:  Oncology (Williston Park)       Date:  2004-09       Impact factor: 2.990

5.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

6.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

Authors:  S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

7.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Authors:  Román Pérez-Soler; Abraham Chachoua; Lisa A Hammond; Eric K Rowinsky; Mark Huberman; Daniel Karp; James Rigas; Gary M Clark; Pedro Santabárbara; Philip Bonomi
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

8.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.

Authors:  Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Geraldine Skailes; Ernie Marshall; Penella J Woll; Matthew Hatton; Rohit Lal; Richard Jones; Elizabeth Toy; David Chao; Gary Middleton; Sue Bulley; Yenting Ngai; Robin Rudd; Allan Hackshaw; Chris Boshoff
Journal:  Lancet Oncol       Date:  2012-10-16       Impact factor: 41.316
View more
  1 in total

Review 1.  EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Cancer Res       Date:  2019-01       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.